Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 10, 2026

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy

View original at globenewswire.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy DUBAI, United Arab Emirates, July 10, 2026 (GLOBE NEWSWIRE) -- Crypto presale Pepeto moved past $10.431 million, and traction like that in a red market raises one question…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A run from $577 to $2,000 for BNB is about a 3.5x return, turning $1,000 into roughly $3,500.

    60% confidence

  • Pepeto built a zero-fee exchange running on its own token, plus a cross-chain bridge linking Ethereum, BNB Chain, and Solana with no gas cost.

    60% confidence

  • Early BNB buyers entered the 2017 ICO at $0.10 per token when it had barely any market value.

    60% confidence

  • The top BNB price prediction for a full bull cycle is $2,060.

    60% confidence

  • Pepeto sits first among crypto presales this year by capital raised, following the exchange token model.

    60% confidence

  • Pepeto has 420 trillion tokens priced at $0.0000001881, with 30% of supply allocated to presale tokens; a climb to a $300 million market cap would mean roughly 50x, turning $5,000 into $250,000, and matching PEPE's peak would push well past 100x.

    60% confidence

  • BNB is trading near $577.

    60% confidence

Data points we hold from this source

Pepeto · token price0.0000001881 USD
Pepeto · funding raised10.41 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy — Source | Via News | Finance Via News